Publications by authors named "Lisa Kottschade"

Claim this Profile
O
Outcomes in Patients With Immune Checkpoint Inhibitor-Related Myopathy and Prolonged Follow-Up.
Yahel Segal, Georgios Mangioris, Michel Toledano, Lisa Kottschade, Eoin P Flanagan

Neurol Neuroimmunol Neuroinflamm· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Complete pathologic response in advanced melanoma with SFRT and dual checkpoint inhibition.
Jared Hobson, Michael P Grams, Joanina K Gicobi, Dennis Wigle, Lisa A Kottschade

Front Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.
Tina J Hieken, David Zahrieh, Thomas J Flotte, Roxana S Dronca, Evidio Domingo-Musibay, Lisa A Kottschade

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supporting Administrative Time for Advanced Practitioners: A Comprehensive Approach.
Merdith Beaton, Andrea Edwards, Wendy Vogel, Haleigh Mistry, Lisa Kottschade

J Adv Pract Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis.
Antonious Hazim, Irene Riestra Guiance, Jacob Shreve, Gordon Ruan, Damian McGlothlin, Lisa Kottschade

Cancer Immunol Immunother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Ethan Basch, Deborah Schrag, Jennifer Jansen, Sydney Henson, Brenda Ginos, Lisa A Kottschade

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.
Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang, Lisa A Kottschade

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort.
Kelsey B Montgomery, M Chandler McLeod, Danielle K DePalo, Michelle M Dugan, Jonathan S Zager, Lisa A Kottschade

Ann Surg Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.
Jacob J Orme, Henan Zhang, Prashanth Lingamaneni, Yohan Kim, Roxane Lavoie, Lisa A Kottschade

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Infiltrating Lymphocyte Cell Therapy for the Treatment of Advanced Melanoma: From Patient Identification to Posttreatment Management.
Lisa Kottschade, Emily Webb Rodriguez, Susan Harding, Smita Ranjan, Lori Mcintyre

J Adv Pract Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance Comparison of Liquid Chromatography and Paper Spray Ionization with Mass Spectrometry for Measuring Kinase Inhibitors in Human Plasma.
Richard G Lahr, Makenzie Meyer, Leah Nelson, Lisa A Kottschade, Paul J Jannetto

ACS Pharmacol Transl Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane

Melanoma Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Effect Duration of Immune Checkpoint Inhibitor-Related Pancreas Adverse Events.
Ferga C Gleeson, Katie A Dunleavy, Michael J Levy, Ryan M Carr, Mindy L Hartgers, Lisa A Kottschade

Pancreas· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, Vera J Suman, Jill M Schimke, Lisa A Kottschade

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy.
Khalid Jazieh, Lisa Kottschade, Anastasios Dimou

J Immunother Precis Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.
Hannah Barman, Sriram Venkateswaran, Antonio Del Santo, Unice Yoo, Eli Silvert, Lisa A Kottschade

JCO Clin Cancer Inform· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the Role of the Advanced Practice Provider Within the National Cancer Institute Community Oncology Research Program.
Christa M Braun-Inglis, Emily V Dressler, Jamie S Myers, Al B Benson, Marie Flannery, Lisa Kottschade

JCO Oncol Pract· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
Ugur Sener, Mason Webb, William G Breen, Bryan J Neth, Nadia N Laack, Lisa A Kottschade

J Immunother Precis Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Tina J Hieken, Garth D Nelson, Thomas J Flotte, Eric P Grewal, Jun Chen, Lisa A Kottschade

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang

Immunotherapy· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, Adam J Weisbrod, Carrie A Strand, Lisa A Kottschade

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postpartum related intrahepatic cholangiocarcinoma with fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review.
Leslie Washburn, Amit Mahipal, Aminah Jatoi, Lisa Kottschade, Nguyen Tran

J Gastrointest Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers.
Lisa A Kottschade, Casey Fazer-Posorske, Anna J Schwecke

Clin J Oncol Nurs· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Methylated DNA Markers for Melanoma Surveillance.
Calise K Berger, William R Taylor, Douglas W Mahoney, Kelli N Burger, Karen A Doering, Lisa A Kottschade

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis